MHRA licenses first in new class of treatment for endometriosis patients

The UK unit of Hungarian drugmaker Gedeon Richter (RICHT: HB) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a license for Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5 for the symptomatic treatment of endometriosis in adult women of reproductive age who have a history of previous medical or surgical treatment for their endometriosis.

The authorization makes relugolix combination therapy the first (an oral gonadotropin-releasing hormone [GnRH] receptor antagonist) in a new class of treatment licensed in the UK for these women, according to Gedeon Richter.

“The intense pain associated with endometriosis can be crippling and have a devastating impact on people’s lives, from their work to intimate relationships and mental health,” said Professor Andrew Horne, director of the Centre for Reproductive Health, University of Edinburgh, adding: “With limited treatments available in the UK, relugolix combination therapy which is taken in a single, once daily tablet may help people take control of their endometriosis-associated pain.”